



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BAY-1797

Item No. 34229

CAS Registry No.: 2055602-83-8
Formal Name: N-[3-(aminosulfonyl)-4-(3-chlorophenoxy)phenyl]-benzeneacetamide
MF: C₂₀H₁₇ClN₂O₄S
FW: 416.9
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAY-1797 is supplied as a solid. A stock solution may be made by dissolving the BAY-1797 in the solvent of choice, which should be purged with an inert gas. BAY-1797 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of BAY-1797 in these solvents is approximately 30 mg/ml.

Description

BAY-1797 is an antagonist of the purinergic P2X₄ receptor (IC₅₀ = 0.211 μM for the human receptor).¹ It is selective for P2X₄ over P2X₁, P2X₃, and P2X₇ receptors (IC₅₀s = >50, 8.3, and 10.6 μM, respectively, for the human receptors), as well as a panel of G protein-coupled receptors (GPCRs), ion channels, kinases, and transporters at 10 μM. BAY-1797 (50 mg/kg) decreases intraplantar prostaglandin E₂ (PGE₂; Item No. 14010) levels and reduces non-evoked pain-related behavior in the dynamic weight bearing test in a mouse model of inflammatory pain induced by complete Freund's adjuvant (CFA).

Reference

1. Werner, S., Mesch, S., Hillig, R.C., *et al.* Discovery and characterization of the potent and selective P2X₄ inhibitor N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile. *J. Med. Chem.* **62**(24), 11194-11217 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/15/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM